Levi Strauss & Co. To Webcast First Quarter 2026 Earnings Conference Call Mar 24, 2026 4:35 PM Eastern Daylight Time Levi Strauss & Co. To Webcast First Quarter 2026 Earnings Conference Call Share SAN FRANCISCO--(BUSINESS WIRE)--Levi Strauss & Co. (NYSE: LEVI) will host a conference call to discuss the company's financial results for the first quarter ended March 1, 2026. The call will be held on Tuesday, April 7, 2026, at 2 p.m. Pacific Time / 5 p.m. Eastern Time, and will be hosted by Michelle Gass, presi ...

LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION Accessibility StatementSkip NavigationKnow Your Rights: How Basic Inc. v. Levinson Enables Investor RecoveryNEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).YOU MAY BE AFFECTED IF YOU:Lost money on your Ultragenyx investmentPurchased Ultragenyx stock between August 3, 2023 an ...

Core Viewpoint - The article highlights the significant disparity between Paysafe Limited's projected financial performance and its actual results, leading to investor dissatisfaction and legal action [1][2]. Group 1: Financial Projections vs. Actual Results - Paysafe initially projected full-year 2025 revenue of $1,710 - $1,734 million and adjusted EPS of $2.21 - $2.51, but these figures were later revised down to $1,700 - $1,710 million in revenue and $1.83 - $1.88 in adjusted EPS [2][6]. - The company promised organic revenue growth of 6.5% to 8.0%, an Adjusted EBITDA margin of 27.1% to 27.6%, and mid-teens growth in Adjusted EBITDA, reaffirming this outlook multiple times throughout 2025 [3][6]. - Actual results showed a net loss increase from approximately $13 million in Q3 2024 to about $88 million in Q3 2025, with revenue missing consensus estimates [4][6]. Group 2: Allegations and Legal Action - The lawsuit alleges that the gap between the promised and actual performance was not due to unforeseen circumstances, but rather that the company was aware of concentrated merchant risks and banking difficulties while maintaining its optimistic guidance [4][5]. - The complaint emphasizes that companies must disclose known risks associated with their performance projections, highlighting the striking difference between what was promised and what was delivered [5].

Core Viewpoint - Institutional investors in Navan, Inc. are facing potential portfolio losses following the company's IPO, with a class action lawsuit highlighting alleged omissions in the Offering Documents regarding significant increases in sales and marketing expenses [1][3][8]. Group 1: IPO and Stock Performance - Shares of Navan were initially priced at $25 during the IPO but have since dropped to as low as $9.20 prior to the lawsuit being filed [2]. - Institutional investors who purchased shares at the IPO price and held them until December 16, 2025, experienced per-share losses of approximately $12.10 based on the post-disclosure closing price [8]. Group 2: Legal Action and Responsibilities - A class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all individuals and entities that purchased Navan common stock related to the IPO [5]. - The lawsuit claims that Navan's Offering Documents failed to disclose a 39% increase in sales and marketing expenses for the quarter ending October 31, 2025, which misled investors regarding the company's growth and financial metrics [3][8]. - The Private Securities Litigation Reform Act of 1995 supports institutional investors as lead plaintiffs, emphasizing their ability to manage complex securities litigation [3][8]. Group 3: Fiduciary Duties and Recovery Options - Pension funds, mutual funds, and asset managers have fiduciary duties to assess all avenues for loss recovery related to their investments in Navan [3]. - Institutions that do not evaluate participation in securities recoveries may face scrutiny from beneficiaries regarding their oversight responsibilities [8]. - The lead plaintiff appointment does not impose additional financial obligations, as counsel fees are covered from any recovery obtained for the class [8].

Core Viewpoint - A securities class action has been filed against Mereo BioPharma Group plc, focusing on allegations regarding the correlation between bone mineral density (BMD) improvements and fracture reduction in patients with osteogenesis imperfecta (OI) [1][2]. Group 1: Allegations and Claims - The lawsuit claims that Mereo BioPharma's management misrepresented the efficacy of setrusumab, asserting that its ability to increase BMD would lead to reduced fracture rates, while omitting critical data that lacked control group comparisons [3]. - The complaint highlights that management was aware of significant challenges in Phase 3 trials, suggesting that the Phase 2 results could not adequately differentiate setrusumab's effects from improvements due to standard care or placebo effects [4]. Group 2: Industry Context and Investor Concerns - The fundamental issue for investors is whether improvements in BMD can be considered a reliable surrogate endpoint for fracture reduction, as the company consistently reported BMD improvements that did not meet market expectations for clinically meaningful fracture reduction [4]. - The lawsuit also notes that the COSMIC study comparing setrusumab to bisphosphonates did not achieve statistical significance, raising further concerns about the drug's efficacy [6].

LEVI & KORSINSKY, LLP: LAKELAND'S $46M OFFERING ALLEGEDLY CONCEALED ACQUISITION RISKS Accessibility StatementSkip NavigationShareholders Who Acquired Shares in the January 2025 Offering Urged to Review OptionsNEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Lakeland Industries, Inc. (NASDAQ: LAKE).YOU MAY BE AFFECTED IF YOU:Acquired shares in or traceable to the Company's January 2025 public offeringLost money on your Lakeland Ind ...

Core Insights - Planet Fitness has appointed Harmit Singh, Chief Financial and Growth Officer of Levi Strauss & Co., to its Board of Directors, expanding the Board to ten members [2][4]. Company Overview - Planet Fitness is one of the largest and fastest-growing fitness center operators globally, with over 20.8 million members and 2,896 clubs as of December 31, 2025 [4]. - The company aims to enhance people's lives by providing a high-quality fitness experience in a welcoming environment known as the Judgement Free Zone® [4]. Leadership Experience - Harmit Singh brings over 40 years of global commercial and financial leadership experience, having previously served as Executive Vice President and CFO of Hyatt Hotels Corporation and held senior roles at Yum! Brands [3][4]. - Singh has a proven track record in driving growth and value creation, including leading Levi Strauss & Co. through its IPO in 2019 and expanding its store base by approximately 200 stores over five years [2][3]. Strategic Focus - The appointment of Singh is seen as a move to strengthen the Board's financial, strategic, and operational expertise, aligning with the company's goals of delivering long-term value for shareholders [4]. - Singh's experience in finance, corporate strategy, and franchise business models is expected to complement the Board as Planet Fitness pursues initiatives to provide value to members and franchisees [4].

Levi Strauss & Co. (LEVI) discussed its strategic goals for the emerging Blue Tab collection during its presentation at the UBS Global Consumer and Retail Conference. Blue Tab, which is Levi’s newest premium denim line, is the brand’s most elevated offering and ...

Group 1 - The German e-commerce company announced a share buyback program worth up to $347 million [1] - The company's Scayle software unit has expanded its operations in the U.S. market [1] - Scayle secured a partnership with Levi Strauss, indicating growth and collaboration opportunities [1]

Group 1 - UBS Investment Bank is hosting the 2026 Global Consumer Retail Conference, featuring Levi's as a key participant [1] - Harmit Singh, Chief Financial and Growth Officer of Levi's, and Aida Orphan, Vice President of Investor Relations, are representing the company at the conference [1]